Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined with Radiation in Colorectal Cancer

Yu Chang Liu; I. Tsang Chiang; Jing Gung Chung; Jung Hung Hsieh; Chih Hung Chiang; Mao Chi Weng; Fei Ting Hsu; Yuan Hao Lee; Cheng Shyong Chang; Song Shei Lin

doi:10.21873/invivo.12157

Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined with Radiation in Colorectal Cancer

Yu Chang Liu, I. Tsang Chiang, Jing Gung Chung, Jung Hung Hsieh, Chih Hung Chiang, Mao Chi Weng, Fei Ting Hsu, Yuan Hao Lee, Cheng Shyong Chang, Song Shei Lin

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Background: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-ĸB) and compromise patients’ survival. Regorafenib suppresses NF-ĸB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. Materials and Methods: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. Results: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-ĸB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. Conclusion: Regorafenib may enhance the anti-CRC efficacy of RT.

Original language	English (US)
Pages (from-to)	3217-3224
Number of pages	8
Journal	In Vivo
Volume	34
Issue number	6
DOIs	https://doi.org/10.21873/invivo.12157
State	Published - Nov 2020
Externally published	Yes

Keywords

Apoptosis
NF-ĸB
Radiosensitizing effect
Radiotherapy

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
Pharmacology

Access to Document

10.21873/invivo.12157

Cite this

@article{48ed781fb8ab4d6abf5f4092432b1215,

title = "Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined with Radiation in Colorectal Cancer",

abstract = "Background: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-ĸB) and compromise patients{\textquoteright} survival. Regorafenib suppresses NF-ĸB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. Materials and Methods: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. Results: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-ĸB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. Conclusion: Regorafenib may enhance the anti-CRC efficacy of RT.",

keywords = "Apoptosis, NF-ĸB, Radiosensitizing effect, Radiotherapy",

author = "Liu, {Yu Chang} and Chiang, {I. Tsang} and Chung, {Jing Gung} and Hsieh, {Jung Hung} and Chiang, {Chih Hung} and Weng, {Mao Chi} and Hsu, {Fei Ting} and Lee, {Yuan Hao} and Chang, {Cheng Shyong} and Lin, {Song Shei}",

note = "Funding Information: This study were supported by Chang Bing Show Chwan Memorial Hospital (ID: BRD-18010), Taipei Veterans General Hospital, Yuan-Shan/Su-Ao Branch, Yilan (ID: YSVH10904) and Central Taiwan University of Science and Technology (ID: CTU108-P-103), respectively. Publisher Copyright: {\textcopyright} 2020 International Institute of Anticancer Research. All rights reserved.",

year = "2020",

month = nov,

doi = "10.21873/invivo.12157",

language = "English (US)",

volume = "34",

pages = "3217--3224",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined with Radiation in Colorectal Cancer

AU - Liu, Yu Chang

AU - Chiang, I. Tsang

AU - Chung, Jing Gung

AU - Hsieh, Jung Hung

AU - Chiang, Chih Hung

AU - Weng, Mao Chi

AU - Hsu, Fei Ting

AU - Lee, Yuan Hao

AU - Chang, Cheng Shyong

AU - Lin, Song Shei

N1 - Funding Information: This study were supported by Chang Bing Show Chwan Memorial Hospital (ID: BRD-18010), Taipei Veterans General Hospital, Yuan-Shan/Su-Ao Branch, Yilan (ID: YSVH10904) and Central Taiwan University of Science and Technology (ID: CTU108-P-103), respectively. Publisher Copyright: © 2020 International Institute of Anticancer Research. All rights reserved.

PY - 2020/11

Y1 - 2020/11

N2 - Background: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-ĸB) and compromise patients’ survival. Regorafenib suppresses NF-ĸB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. Materials and Methods: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. Results: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-ĸB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. Conclusion: Regorafenib may enhance the anti-CRC efficacy of RT.

AB - Background: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-ĸB) and compromise patients’ survival. Regorafenib suppresses NF-ĸB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. Materials and Methods: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. Results: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-ĸB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. Conclusion: Regorafenib may enhance the anti-CRC efficacy of RT.

KW - Apoptosis

KW - NF-ĸB

KW - Radiosensitizing effect

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85095584722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095584722&partnerID=8YFLogxK

U2 - 10.21873/invivo.12157

DO - 10.21873/invivo.12157

M3 - Article

C2 - 33144426

AN - SCOPUS:85095584722

SN - 0258-851X

VL - 34

SP - 3217

EP - 3224

JO - In Vivo

JF - In Vivo

IS - 6

ER -

Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined with Radiation in Colorectal Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this